All Outputs (3)

UK Multicenter Prospective Evaluation of the Leibovich Score in Localized Renal Cell Carcinoma: Performance has Altered Over Time (2019)
Journal Article
Vasudev, N. S., Hutchinson, M., Trainor, S., Ferguson, R., Bhattarai, S., Adeyoju, A., …Banks, R. E. (2019). UK Multicenter Prospective Evaluation of the Leibovich Score in Localized Renal Cell Carcinoma: Performance has Altered Over Time. Urology, https://doi.org/10.1016/j.urology.2019.09.044

© 2019 The Authors Objective: To examine changes in outcome by the Leibovich score using contemporary and historic cohorts of patients presenting with renal cell carcinoma (RCC) Patients and Methods: Prospective observational multicenter cohort study... Read More about UK Multicenter Prospective Evaluation of the Leibovich Score in Localized Renal Cell Carcinoma: Performance has Altered Over Time.

Meta-Analysis in Metastatic Uveal Melanoma to Determine Progression-Free and Overall Survival Benchmarks: an International Rare Cancers Initiative (IRCI) Ocular Melanoma study (2019)
Journal Article
Khoja, L., Atenafu, E., Suciu, S., Leyvraz, S., Sato, T., Marshall, E., …Joshua, A. (2019). Meta-Analysis in Metastatic Uveal Melanoma to Determine Progression-Free and Overall Survival Benchmarks: an International Rare Cancers Initiative (IRCI) Ocular Melanoma study. Annals of Oncology, 30(8), 1370-1380. https://doi.org/10.1093/annonc/mdz176

Background: Despite the completion of numerous phase II studies, a standard of care treatment has yet to be defined for metastatic uveal melanoma (mUM). To determine benchmarks of progression free survival (PFS) and overall survival (OS), we carried... Read More about Meta-Analysis in Metastatic Uveal Melanoma to Determine Progression-Free and Overall Survival Benchmarks: an International Rare Cancers Initiative (IRCI) Ocular Melanoma study.

The genetic vulnerability to cisplatin ototoxicity: a systematic review (2019)
Journal Article
Edvall, N. K., Cederroth, C. R., Tserga, E., Nandwani, T., Edvall, N. K., Bulla, J., …Baguley, D. M. (2019). The genetic vulnerability to cisplatin ototoxicity: a systematic review. Scientific Reports, 9, Article 3455. https://doi.org/10.1038/s41598-019-40138-z

Ototoxicity is one of the major side-effects of platinum-based chemotherapy, in particular cisplatin (cis-diammine dichloroplatinum II). To our knowledge, no systematic review has previously provided a quantitative summary estimate of the impact of g... Read More about The genetic vulnerability to cisplatin ototoxicity: a systematic review.